| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.071 | 0.03 |
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | 0.076 | 0.03 |
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.08 | 0.03 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.079 | 0.03 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | 0.065 | 0.03 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | 0.065 | 0.03 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | -0.073 | 0.03 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.069 | 0.03 |
| mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | 0.15 | 0.03 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.03 |